Suppr超能文献

I-neb 自适应雾化输送(AAD)系统的体外特性分析。

In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.

机构信息

Philips Respironics, Respiratory Drug Delivery Ltd, Chichester, United Kingdom.

出版信息

J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S11-20. doi: 10.1089/jamp.2009.0792.

Abstract

The in vitro characterization of device-related parameters such as the rate of aerosol output, total aerosol output, particle size, and fine particle fraction, is essential when assessing the potential performance of a nebulizer or making comparisons with other nebulizers as they are indicative of potential clinical performance. This article reviews a number of in vitro studies designed to characterize the I-neb Adaptive Aerosol Delivery (AAD) System in terms of drug delivery (particle size, residual, reproducibility, precise dose delivery, dose equivalence), in terms of drug-related performance (osmolality, surface tension, viscosity), and in terms of nebulizer orientation during operation. The results of the in vitro tests of drug delivery indicate that the I-neb AAD System is suitable for delivery of aqueous solutions by nebulization. The evaluation of equivalent doses between the I-neb AAD System (metered dose) and a conventional jet nebulizer (delivered dose), demonstrates that the amount of drug required to deliver the same dose is up to five times less with the I-neb AAD System due to the low residual and controlled drug delivery. The lack of change in osmolality during nebulization might be of importance as it presents an opportunity for delivery of drugs to patients with hyperreactive airways, or where a specific tonicity of the formulation is required. The physicochemical characteristics (surface tension, viscosity) of a number of drugs delivered with the I-neb AAD System highlights some of the demands created by existing and new drug formulations. Finally, the study of the impact of nebulizer orientation shows how important it is to also consider how the nebulizer will actually be physically used by the patient rather than solely under standard conditions used within the laboratory.

摘要

在评估雾化器的潜在性能或与其他雾化器进行比较时,对与设备相关的参数(如气溶胶输出率、总气溶胶输出量、颗粒大小和细颗粒分数)进行体外特性分析至关重要,因为这些参数可反映潜在的临床性能。本文回顾了一些旨在描述 I-neb 自适应气溶胶输送(AAD)系统的体外研究,这些研究涉及药物输送(颗粒大小、残留量、重现性、精确剂量输送、剂量等效性)、药物相关性能(渗透压、表面张力、粘度)和操作过程中的雾化器方向。药物输送的体外测试结果表明,I-neb AAD 系统适用于通过雾化输送水溶液。对 I-neb AAD 系统(计量剂量)和传统射流雾化器(输送剂量)之间等效剂量的评估表明,由于残留量低且药物输送得到控制,因此使用 I-neb AAD 系统输送相同剂量所需的药物量最多可减少五倍。在雾化过程中渗透压不变可能很重要,因为这为向高反应性气道的患者或需要特定配方渗透压的患者输送药物提供了机会。通过 I-neb AAD 系统输送的一些药物的理化特性(表面张力、粘度)突出了现有和新药物配方带来的一些需求。最后,对雾化器方向影响的研究表明,考虑患者实际使用雾化器的方式,而不仅仅是在实验室中使用的标准条件,是非常重要的。

相似文献

1
In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S11-20. doi: 10.1089/jamp.2009.0792.
2
The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S1-10. doi: 10.1089/jamp.2009.0791.
3
The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S55-9. doi: 10.1089/jamp.2009.0793.
5
Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):iii-v. doi: 10.1089/jamp.2010.0818.
6
Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S45-54. doi: 10.1089/jamp.2009.0777.
8
Evaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary disease.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S61-70. doi: 10.1089/jamp.2009.0767.
9
Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S37-43. doi: 10.1089/jamp.2009.0786.
10
The function and performance of aqueous aerosol devices for inhalation therapy.
J Pharm Pharmacol. 2016 May;68(5):556-78. doi: 10.1111/jphp.12541. Epub 2016 Apr 8.

引用本文的文献

3
Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives.
Pharmaceutics. 2021 Sep 12;13(9):1455. doi: 10.3390/pharmaceutics13091455.
4
Future Trends in Nebulized Therapies for Pulmonary Disease.
J Pers Med. 2020 May 10;10(2):37. doi: 10.3390/jpm10020037.
5
Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.
J Aerosol Med Pulm Drug Deliv. 2019 Oct;32(5):317-339. doi: 10.1089/jamp.2018.1508. Epub 2019 Jul 9.
6
Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial.
Pulm Circ. 2018 Oct-Dec;8(4):2045894018798921. doi: 10.1177/2045894018798921. Epub 2018 Aug 20.
7
Numerical Model to Characterize the Size Increase of Combination Drug and Hygroscopic Excipient Nanoparticle Aerosols.
Aerosol Sci Technol. 2011 Jan 1;45(7):884-899. doi: 10.1080/02786826.2011.566592.
8
Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):iii-v. doi: 10.1089/jamp.2010.0818.
9
The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S1-10. doi: 10.1089/jamp.2009.0791.

本文引用的文献

1
Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S37-43. doi: 10.1089/jamp.2009.0786.
3
The influence of fluid physicochemical properties on vibrating-mesh nebulization.
Int J Pharm. 2007 Jul 18;339(1-2):103-11. doi: 10.1016/j.ijpharm.2007.02.035. Epub 2007 Mar 6.
7
Design principles of liquid nebulization devices currently in use.
Respir Care. 2002 Nov;47(11):1257-75; discussion 1275-8.
8
History and evolution of aerosolized therapeutics: overview and introduction.
Chest. 2001 Sep;120(3 Suppl):87S-88S. doi: 10.1378/chest.120.3_suppl.87s.
9
European Respiratory Society Guidelines on the use of nebulizers.
Eur Respir J. 2001 Jul;18(1):228-42. doi: 10.1183/09031936.01.00220001.
10
Comparison of drug delivery from conventional versus "Venturi" nebulizers.
Eur Respir J. 1997 Nov;10(11):2479-83. doi: 10.1183/09031936.97.10112479.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验